

# David Malka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6063163/publications.pdf>

Version: 2024-02-01

59  
papers

2,801  
citations

257450

24  
h-index

182427

51  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3942  
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 537-546.	2.5	12
2	Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 262-271.	1.6	59
3	Reply to M. Salati et al. <i>Journal of Clinical Oncology</i> , 2022, , JCO2200057.	1.6	0
4	Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies. <i>European Journal of Cancer</i> , 2022, 164, 80-87.	2.8	12
5	PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. <i>Cancer Discovery</i> , 2022, 12, 1435-1448.	9.4	28
6	Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial. <i>Nature Medicine</i> , 2022, 28, 1224-1231.	30.7	38
7	Safety and Efficacy of Bevacizumab in Cancer Patients with Inflammatory Bowel Disease. <i>Cancers</i> , 2022, 14, 2914.	3.7	3
8	Aflibercept-LV5FU2 as first-line treatment of non-resectable metastatic colorectal cancers: Results of the FOLFA randomized phase II trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 3555-3555.	1.6	0
9	An appraisal of emerging second line therapies for metastatic colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 165-179.	3.0	2
10	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. <i>European Journal of Cancer</i> , 2021, 142, 147-149.	2.8	2
11	Immunotherapy in Advanced Biliary Tract Cancers. <i>Cancers</i> , 2021, 13, 1569.	3.7	19
12	Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 401-409.	4.1	10
13	Upper Gastrointestinal Lesions during Endoscopy Surveillance in Patients with Lynch Syndrome: A Multicentre Cohort Study. <i>Cancers</i> , 2021, 13, 1657.	3.7	7
14	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 3242-3250.	1.6	35
15	Local treatment of pancreatic cancer metastases: A multicenter French study of the AGEO group. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101607.	1.5	3
16	Cholangiocarcinoma with STRN-ALK translocation treated with ALK inhibitors. <i>Digestive and Liver Disease</i> , 2021, 53, 1664-1665.	0.9	6
17	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience. <i>Cancers</i> , 2021, 13, 5366.	3.7	17
18	Targeting HGF/c-Met Axis Decreases Circulating Regulatory T Cells Accumulation in Gastric Cancer Patients. <i>Cancers</i> , 2021, 13, 5562.	3.7	6

#	ARTICLE	IF	CITATIONS
19	Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. <i>Gastric Cancer</i> , 2020, 23, 73-81.	5.3	75
20	Immune scores in colorectal cancer: Where are we?. <i>European Journal of Cancer</i> , 2020, 140, 105-118.	2.8	50
21	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020, 137, 117-126.	2.8	16
22	Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. <i>International Journal of Cancer</i> , 2020, 147, 2190-2198.	5.1	288
23	Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX). <i>European Journal of Cancer</i> , 2020, 136, 25-34.	2.8	6
24	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. <i>Journal of Hepatology</i> , 2020, 73, 1109-1117.	3.7	25
25	An update on treatment options for pancreatic adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987556.	3.2	144
26	FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. <i>European Journal of Cancer</i> , 2019, 115, 97-106.	2.8	29
27	Adjuvant capecitabine in biliary tract cancer: a standard option?. <i>Lancet Oncology</i> , The, 2019, 20, 606-608.	10.7	26
28	Renal toxicities associated with pembrolizumab. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 81-88.	2.9	101
29	Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE) Tj ETQq1 1 0.784314 rgBT /Over 658-667.	1.6	357
30	Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. <i>Oncologist</i> , 2019, 24, e1331-e1340.	3.7	20
31	5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy. <i>Anti-Cancer Drugs</i> , 2019, 30, 313-317.	1.4	14
32	Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice. <i>Clinical Colorectal Cancer</i> , 2019, 18, e117-e129.	2.3	53
33	Prognosis and chemosensitivity of non-V600E BRAF mutations in metastatic colorectal carcinoma (mCRC): An AGEO French multicenter retrospective cohort.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3575-3575.	1.6	2
34	Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4079-4079.	1.6	94
35	Oxaliplatin and 5-fluorouracil (FOLFOX) in advanced well-differentiated digestive neuroendocrine tumors: A multicenter national retrospective study from the French Group of Endocrine Tumors (GTE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4104-4104.	1.6	2
36	Circulating oncometabolite D-2-hydroxyglutarate enantiomer is a surrogate marker of isocitrate dehydrogenase mutated intrahepatic cholangiocarcinomas. <i>European Journal of Cancer</i> , 2018, 90, 83-91.	2.8	28

#	ARTICLE	IF	CITATIONS
37	Chemotherapy for pancreatic cancer: the rise of multidrug regimens. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 659-660.	8.1	2
38	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. <i>European Journal of Cancer</i> , 2018, 100, 94-103.	2.8	20
39	FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4000-4000.	1.6	43
40	Gemcitabine plus nab-paclitaxel until progression or given sequentially with 5-fluorouracil plus irinotecan (FOLFIRI.3) for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC): A randomized phase II study (PRODIGE 37-FIRGEMAX).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4107-4107.	1.6	7
41	Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects. <i>European Journal of Cancer</i> , 2017, 79, 15-22.	2.8	42
42	Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?. <i>European Journal of Cancer</i> , 2017, 81, 161-173.	2.8	27
43	First-line treatment in metastatic colorectal cancer: Important or crucial?. <i>European Journal of Cancer</i> , 2017, 84, 363-366.	2.8	4
44	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 3640-3646.	1.5	25
45	Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis. <i>Seminars in Oncology</i> , 2017, 44, 114-128.	2.2	14
46	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017, 87, 122-130.	2.8	120
47	Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials. <i>BMC Cancer</i> , 2017, 17, 262.	2.6	16
48	Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study. <i>Neuroendocrinology</i> , 2017, 105, 26-34.	2.5	11
49	Feasibility of Capecitabine and Oxaliplatin Combination Chemotherapy Without Central Venous Access Device in Patients With Stage III Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2016, 15, 250-256.	2.3	12
50	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 78-83.	0.5	0
51	Systemic treatment of advanced hepatocellular carcinoma: From disillusion to new horizons. <i>European Journal of Cancer</i> , 2015, 51, 327-339.	2.8	63
52	Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. <i>Gastroenterology</i> , 2015, 149, 1017-1029.e3.	1.3	76
53	Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: Long-term results of the UNICANCER ACCORD 16 phase II trial. <i>Radiotherapy and Oncology</i> , 2015, 114, 415-416.	0.6	35
54	Is primary tumour resection associated with survival improvement in patients with colorectal cancer and unresectable synchronous metastases? A pooled analysis of individual data from four randomised trials. <i>European Journal of Cancer</i> , 2015, 51, 166-176.	2.8	105

#	ARTICLE	IF	CITATIONS
55	A Simple Tumor Load-Based Nomogram for Surgery in Patients with Colorectal Liver and Peritoneal Metastases. <i>Annals of Surgical Oncology</i> , 2014, 21, 2052-2058.	1.5	52
56	Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T AGE0 randomised phase II study (FIRGEM). <i>European Journal of Cancer</i> , 2014, 50, 3116-3124.	2.8	27
57	Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 819-828.	10.7	345
58	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: Lipiodol vs. drug-eluting beads. <i>Journal of Hepatology</i> , 2012, 56, 609-617.	3.7	161
59	Capecitabine: Still a Standard Option in the Adjuvant Setting of Biliary Tract Cancer?. <i>Journal of Clinical Oncology</i> , 0, , .	1.6	1